Royalty Pharma acquires royalties on Lexiscan

Manjula Puthenedam, PhD, | April 05, 2011 | Health Imaging | Cardiac Imaging

Royalty Pharma has acquired the rights to certain royalties payable on sales of the pharmacologic stress agent Lexiscan and the antibiotic Cubicin from an undisclosed seller for a cash payment of $487 million.

Lexiscan (regadenoson) is a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Lexiscan was co-developed by CV Therapeutics (now Gilead) and Astellas, said the New York City-based Royalty Pharma.

Cubicin (daptomycin for injection) is a bacteriocidal, IV antibiotic with activity against MRSA, or methicillin-resistant staphylococcus aureus, added the company.

Manjula Puthenedam, PhD,

Around the web

Cardiovascular Business

Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business

FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.

Royalty Pharma acquires royalties on Lexiscan

Related Content

Around the web